Supplementary Table S2 summarizes that low RASSF10 expression is associated with reduced 5 year survival rates of cancers: kidney cancer, 24% (papillary, significant) and 12% (clear cell, significant); head and neck cancer, 18% (significant); lymphoma, 22% (mantle cell, significant) and 5% (B-cell); thymoma, 8%; liver cancer, 34% (significant); lung cancer, 18% (significant); gastric cancer, 7%; and breast cancer, 21% (significant). In summary, we observed that the levels of RASSF10 expression/methylation are suitable for prognosis and diagnosis of various cancer types in humans. This evidence concerns the gene RASSF10 and head and neck cancer.